Wolverine Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $4.37M | Buy |
80,900
+12,900
| +19% | +$738K | ﹤0.01% | 1485 |
|
|
2025
Q2 | $3.75M | Buy |
68,000
+34,500
| +103% | +$2.03M | ﹤0.01% | 1243 |
|
|
2025
Q1 | $2.39M | Sell |
33,500
-9,300
| -22% | -$626K | ﹤0.01% | 1477 |
|
|
2024
Q4 | $2.8M | Buy |
42,800
+9,600
| +29% | +$643K | ﹤0.01% | 1682 |
|
|
2024
Q3 | $2.34M | Buy |
+33,200
| New | +$2.78M | ﹤0.01% | 1571 |
|
|
2024
Q2 | – | Sell |
-16,000
| Closed | -$1.4M | – | 4505 |
|
|
2024
Q1 | $1.4M | Buy |
+16,000
| New | +$1.43M | ﹤0.01% | 1893 |
|
|
2023
Q4 | – | Sell |
-32,500
| Closed | -$2.88M | – | 4502 |
|
|
2023
Q3 | $2.88M | Buy |
32,500
+8,500
| +35% | +$756K | ﹤0.01% | 1337 |
|
|
2023
Q2 | $2.13M | Sell |
24,000
-12,300
| -34% | -$1.16M | ﹤0.01% | 1446 |
|
|
2023
Q1 | $3.46M | Buy |
36,300
+14,900
| +70% | +$1.54M | 0.01% | 1034 |
|
|
2022
Q4 | $2.21M | Buy |
21,400
+10,700
| +100% | +$1M | ﹤0.01% | 1317 |
|
|
2022
Q3 | $910K | Buy |
10,700
+500
| +5% | +$44.5K | ﹤0.01% | 2058 |
|
|
2022
Q2 | $856K | Buy |
10,200
+700
| +7% | +$55.7K | ﹤0.01% | 2049 |
|
|
2022
Q1 | $740K | Sell |
9,500
-8,500
| -47% | -$711K | ﹤0.01% | 2777 |
|
|
2021
Q4 | $1.6M | Sell |
18,000
-8,500
| -32% | -$701K | ﹤0.01% | 2094 |
|
|
2021
Q3 | $2.04M | Sell |
26,500
-1,600
| -6% | -$126K | ﹤0.01% | 2135 |
|
|
2021
Q2 | $2.35M | Sell |
28,100
-8,600
| -23% | -$682K | ﹤0.01% | 1817 |
|
|
2021
Q1 | $2.75M | Sell |
36,700
-23,600
| -39% | -$1.93M | ﹤0.01% | 1622 |
|
|
2020
Q4 | $5.24M | Sell |
60,300
-10,300
| -15% | -$817K | 0.01% | 1026 |
|
|
2020
Q3 | $5.37M | Buy |
70,600
+23,100
| +49% | +$2.34M | 0.01% | 819 |
|
|
2020
Q2 | $5.8M | Buy |
47,500
+9,600
| +25% | +$954K | 0.02% | 729 |
|
|
2020
Q1 | $3.13M | Sell |
37,900
-17,400
| -31% | -$1.5M | 0.01% | 1025 |
|
|
2019
Q4 | $4.68M | Buy |
55,300
+500
| +0.9% | +$37.8K | 0.01% | 1150 |
|
|
2019
Q3 | $3.74M | Buy |
+54,800
| New | +$4.22M | 0.01% | 1036 |
|
|
2019
Q2 | – | Sell |
-35,100
| Closed | -$3.12M | – | 4424 |
|
|
2019
Q1 | $3.12M | Sell |
35,100
-4,500
| -11% | -$417K | 0.01% | 1179 |
|
|
2018
Q4 | $3.31M | Buy |
39,600
+14,500
| +58% | +$1.38M | 0.01% | 1072 |
|
|
2018
Q3 | $2.43M | Buy |
25,100
+7,400
| +42% | +$739K | 0.01% | 1499 |
|
|
2018
Q2 | $1.44M | Hold |
17,700
| – | – | ﹤0.01% | 1887 |
|
|
2018
Q1 | $1.44M | Sell |
17,700
-3,800
| -18% | -$326K | ﹤0.01% | 1887 |
|
|
2017
Q4 | $1.92M | Buy |
21,500
+9,700
| +82% | +$843K | 0.01% | 1589 |
|
|
2017
Q3 | $1.1M | Buy |
+11,800
| New | +$1.04M | ﹤0.01% | 1832 |
|
|
2017
Q1 | – | Sell |
-11,000
| Closed | -$911K | – | 4276 |
|
|
2016
Q4 | $911K | Sell |
11,000
-100
| -0.9% | -$8.6K | ﹤0.01% | 1990 |
|
|
2016
Q3 | $1.03M | Sell |
11,100
-2,700
| -20% | -$254K | ﹤0.01% | 1833 |
|
|
2016
Q2 | $1.08M | Buy |
+13,800
| New | +$1.17M | 0.01% | 1532 |
|
Other funds holding BMRN
Wolverine Trading's BMRN Position: Q3 2025 in Review
Wolverine Trading increased its BioMarin Pharmaceuticals (BMRN) stake by 66% in Q3 2025, buying an estimated $191K and bringing the position to 8,435 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #3817.
Wolverine Trading first reported a position in BMRN in Q2 2016 and has held it in 23 quarters since. The position peaked at $1.76M in Q4 2021. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.
- Wolverine Trading held 8,435 shares of BioMarin Pharmaceuticals worth $456K as of Q3 2025.
- Wolverine Trading bought 3,346 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $191K.
- BioMarin Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #3817 holding.
- Wolverine Trading first reported a position in BioMarin Pharmaceuticals in Q2 2016 and has held it in 23 quarters since.
- Wolverine Trading's BioMarin Pharmaceuticals position peaked at $1.76M in Q4 2021.
- 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.